Key Takeaways:
GeneDx Holdings Corp. (NASDAQ: WGS) reported a first-quarter loss per share of $0.28, widely missing analyst estimates, yet its stock saw a modest gain.
"Our focus on transitioning to whole genome sequencing and managing reimbursement dynamics is crucial for our long-term success," CEO Katherine Stueland said on the company's earnings call.
Revenue for the quarter was $102.3 million, falling short of the expected $112.45 million. The earnings per share of -$0.28 represented a significant miss from the consensus forecast of -$0.01. The company attributed the shortfall to lower reimbursement rates and underperformance in non-core business lines.
Despite the misses, shares rose 0.69% in premarket trading on May 4. The company guided for a return to adjusted profitability for the full year, supported by a newly announced $25 million operational expenditure reduction plan.
The genomics company saw strong underlying demand in its core business, with exome and genome test volumes increasing by 34 percent compared to the same period last year. However, the revenue impact was blunted by a product mix shift toward whole genome sequencing, which currently has a lower average reimbursement rate than exome sequencing. The company stated the lower reimbursement rate accounted for a $5.5 million impact on revenue.
GeneDx revised its full-year 2026 revenue guidance down by 12 percent to a new range of $475 million to $490 million. The company still projects exome and genome volume growth of at least 30 percent for the year and expects to achieve full-year adjusted profitability.
The unexpected stock rally suggests investors are prioritizing strong volume growth and cost discipline over the headline revenue miss. The company's ability to improve reimbursement rates for whole genome sequencing will be the key factor for shareholders to watch in the upcoming quarters.
This article is for informational purposes only and does not constitute investment advice.
